Cagrilintide vs Human Growth Hormone (HGH)
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
Cagrilintide
Cagrilintide is a long-acting amylin analog in development, showing promising results when combined with semaglutide (CagriSema). Amylin is a hormone co-secreted with insulin that promotes satiety.
Full details →Human Growth Hormone (HGH)
Human Growth Hormone (somatropin) is a 191-amino acid protein identical to naturally produced GH. FDA-approved for growth hormone deficiency, Turner syndrome, and other conditions. Widely used off-label for anti-aging and performance.
Full details →Side-by-Side Comparison
| Aspect | Cagrilintide | Human Growth Hormone (HGH) |
|---|---|---|
| Dose Range | 300 mcg–4.5 mg | 200 mcg–2 mg |
| Frequency | Less than daily | 1x daily |
| Cycle Length | 26–68 weeks | 12–24 weeks |
| Route | subcutaneous | subcutaneous |
| Mechanism | Activates amylin receptors (calcitonin receptor with RAMP proteins) to slow gastric emptying, suppress glucagon secretion, and reduce food intake through central satiety mechanisms distinct from GLP-1. | Binds to GH receptors throughout the body, stimulating IGF-1 production in the liver. Promotes protein synthesis, fat metabolism, and cellular regeneration across multiple tissues. |
| Typical Dosage | Clinical trials: 2.4mg weekly as monotherapy or in combination with semaglutide 2.4mg (CagriSema). Optimal dosing still being determined. | Medical: 0.1-0.3mg/kg/week divided into daily doses. Anti-aging: 1-2 IU daily. Performance: 2-6 IU daily, sometimes higher. |
| Administration | Subcutaneous injection once weekly. Currently only available in clinical trials - not yet FDA approved. | Subcutaneous injection, preferably at night to mimic natural pulsatile release. Rotate injection sites. Store refrigerated. |
| Side Effects | Nausea, vomiting, diarrhea, constipation similar to other incretin-based therapies. Combination with semaglutide may increase GI effects initially. | Joint pain, water retention, carpal tunnel syndrome, potential insulin resistance, and acromegaly features with long-term high doses. |
| Best For |
What They Have in Common
Cagrilintide, Human Growth Hormone (HGH) are both commonly used for:
Key Differences
Unique to Human Growth Hormone (HGH):
Which Has Stronger Evidence?
| Goal | Cagrilintide | Human Growth Hormone (HGH) |
|---|---|---|
| Fat Loss | high | high |
Key Studies
Cagrilintide
- Efficacy and safety of co-administered cagrilintide and semaglutide versus semaglutide alone in adults with overweight or obesity with or without type 2 diabetes in Japan and Taiwan (REDEFINE 5): a multicentre, randomised, active-controlled, phase 3a trial.
The lancet. Diabetes & endocrinology, 2026
- A cross-species atlas of the dorsal vagal complex reveals neural mediators of the effects of cagrilintide on energy balance.
Nature metabolism, 2026
- Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes.
The New England journal of medicine, 2025
Human Growth Hormone (HGH)
- Transgenic Artifacts Caused by Passenger Human Growth Hormone.
Trends in endocrinology and metabolism: TEM, 2018
- [Human growth hormone and Turner syndrome].
Anales de pediatria (Barcelona, Spain : 2003), 2017
- Significance of the disulphide bonds of human growth hormone.
Endokrynologia Polska, 2013
Ready to Learn More?
Looking for trusted sources?